Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Health better health, better life Health Corporate Presentation mariposa mariposa February 2016 1 Forward Looking Statements Except for statutory liability which cannot be excluded, each of Mariposa Health, its officers, employees and advisers expressly disclaims any responsibility for the accuracy or completeness of the material contained in this presentation and excludes all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission there from. Mariposa Health accepts no responsibility to update any person regarding any inaccuracy, omission or change in information in this presentation or any other information made available to a person nor any obligation to furnish the person with any further information. Investment in Mariposa Health should be considered speculative. mariposa This presentation contains certain statements which may constitute "forward-looking statements.” Such statements are only predictions and are subject to inherent risks and uncertainties which could cause actual values, results, performance or achievements to differ materially from those expressed, implied or projected in any forward-looking statements. No representation or warranty, express or implied, is made by Mariposa Health that the material contained in this presentation will be achieved or prove to be correct. Health 2 Introduction rd 1) oral bacterial vaccine, 2) anti-inflammatory/anti-oxidant Both are complementary to current treatments Health Out-licensed for development & marketing in China Target on-sale or out-license to larger pharma by end 2018 mariposa Our market focus is COPD, the 3 leading cause of death in the US 2 products in Phase 2 clinical trials: 3 Company Information Shareholders: 65 Shares on issue: 9,881,211 Warrants exercisable at listing: 438,789 SEC filings: Forms 10K, 10Q Health Fully diluted share structure: 10,320,000 mariposa Mariposa Health Inc was formed merger of Mariposa Health Ltd (Australia) and a US shell 4 Board & Management Margaret Bridges Yasuo Aoki Margaret Dunkley TA-270 Project Specialist BSc. PhD. Pharmacologist, Dainippon Ink & Chemical (Japan), Activus Pharma (Japan) HI-164 Project Specialist BSc, PhD MBA. Immunologist, University of Newcastle, Hunter Immunology Health Kevin Lynn Chairman & CEO BSc, PhD, MBA. Pharmaceutical development & marketing (CibaGeigy, Novartis). Director, CFO CA, FFIN, FICD. Past CFO & Director Australian listed small & midcap companies Non-executive Director B.Eng. Strategy consultant including Pharmaceutical & medical services, Asia area mariposa Phillip Comans 5 Chronic Obstructive Pulmonary Disease (COPD) leading cause of death in the United States. 12.7 million people have been diagnosed with COPD, up to 24 million have the disease without being aware. . COPD causes serious long-term disability and early death. Source: American Lung Association, 2016 http://www.lung.org/lung-health-and-diseases/lung-disease-lookup/copd/learn-about-copd/howserious-is-copd.html Health At this time there is no cure, and the number of people dying from COPD is growing. mariposa rd 3 COPD: We address a major market $6billion (US) Disease costs: $30-40billion annual (US) Drug sales: $6billion (US) Major drugs: Spiriva (BII), Advair (GSK) Source: American Lung Association, 2016 http://www.lung.org/lung-health-and-diseases/lung-disease-lookup/copd/learn-about-copd/howserious-is-copd.html Health Our drugs are complementary to existing treatments mariposa Hospital costs: Market dynamics Generics bring low pricing Aim: Unique benefits, Higher prices & Large market Health Introduction of numerous similar (bronchodilator + steroid) Gaps in existing treatment: Much room to reduce “Medical interventions” mariposa Market leaders coming off patent 8 COPD: A complex disease Faulty immune activity Host factors, exogenous oxidative stress and amplifying mechanisms Recurring bacterial infections Lung Inflammation Oxidative Stress Repair Mechanisms Health COPD Pathology Proteases mariposa Cigarette Smoke Biomass particles and particulates From Global Guideline for COPD : GOLD 9 Two drugs: Place in treatment Host factors, exogenous oxidative stress and amplifying mechanisms Faulty immune activity TA-270: Anti-inflammatory Lung Inflammation TA-270: Anti-oxidant HI-164: Bacterial vaccine Oxidative Stress Proteases Health COPD Pathology mariposa Cigarette Smoke Biomass particles and particulates Repair Mechanisms From Global Guideline for COPD : GOLD TA-270: Inhibits 5-lipoxygenase and peroxynitrite HI-164: Non-typeable H. influenzae 10 HI-164 One Phase 1 study Two Phase 2 studies of 6 & 9 months duration 21 hospital centers mariposa Oral, mucosal vaccine to Nontypeable H. influenza Health 11 HI-164-OV: Reduction in exacerbations of COPD Phase 2 studies in COPD patients (post-hoc analysis: Studies H-002/4, HI-005) Exacerbations (n) p = 0.0009 p = 0.002 p = 0.01 Study designs COPD patients, m or f Randomised, db, pc HI002/4, n=140; HI-005, n= 90 Treatment with oral HI-164 tablets or placebo once daily for 3 days, repeated after 4 & 8 weeks Duration of study: HI002/4 6 months; HI005 9 months Patients <65 years All p-values: Statistical differences, active vs placebo (N= HI-002/004, A 68, P 72; HI-005, A 34, P 56) Health All ages HI-164OV mariposa Placebo (existing treatment) Definition of a moderate to severe exacerbation includes: + Patient is admitted to hospital or prescribed corticosteroid or antibiotic to treat the exacerbation ++ Patient is admitted to hospital or prescribed corticosteroid to treat the exacerbation 12 Increased time to first episode of COPD (Post hoc analysis, Patients aged <65years, Study HI-005; n= a34, p56) mariposa 1.00 Log-rank test, p<0.01 Survival distribution p = 0.02 HI-164OV Placebo 0.75 0.50 Health 0.25 0.0 50 150 250 Days to first exacerbation 350 13 HI-164OV: Effects on hospital admissions Placebo (n= 56) P-value 0.3 0.7 0.028 1.63 4.02 0.032 0.2 0.4 0.086 Health Hospital admission rate per patient (mean) Duration of hospitalization (mean, days) Admission rate for acute exacerbations (mean) Active (n= 35) mariposa (Post hoc analysis, Patients aged <65years, Study HI-005) Reduction in exacerbations and hospital admissions was also observed in Study HI-002/004 14 Next trial Study in patients aged 65 years or less with COPD (chronic bronchitis) mariposa Phase 2 clinical trial under IND Health 15 TA-270 Five Phase 1 studies Four Phase 2 studies of 1-4 weeks duration Studies in Japan, EU and UK Improve lung epithelium, oxygenation of RBC Health Improve chronic lung capacity mariposa Oral, inhibitor of 5-lipoxygenase (5-LO) and peroxynitrite (ONOO-) 16 TA-270: Dual Mode of Action, More Potent Effects 2. Superior Inhibition of leukotriene pathway Inhibition of 5-LO (%) Inhibition of peroxynitrite (%) 100 mariposa 1. Superior free radical scavenging TA-270 Inhibition of LTB4 (%) TA-270 TA-270 80 60 40 20 0 1.0E-08 1.0E-07 1.0E-06 1.0E-05 1.0E-04 1.00E-09 1.00E-08 1.00E-07 1.00E-06 1.00E-05 1.00E-09 1.00E-08 Concentration (mol/L) TA-270 N-Acetylcysteine Tyrosine Zileuton 1.00E-07 1.00E-06 1.00E-05 Health -20 - Superior free-radical scavenging to N’acetylcysteine - More potent 5-LO and LTB4 inhibition than Zileuton 17 TA-270: Complementary improvements in breathing (Exploratory Phase 2; Moderate to severe COPD) Increase in FEV1 from Baseline (mL) Patients in Study TA-007 may have been taking Spiriva, Advair or a similar product Study TA-007, Open label Phase 2, n=13 Source: TA-270 data on file, FDA approved information, publications; TA-270 shows change vs Baseline, others 18 change vs. placebo Health • • mariposa Current medications Path forward Preliminary, inhaled dose form mariposa Reformulation of oral form: patent life to 2036 Health 19 Path to Value II H-164 COPD (Chronic bronchitis) Manufacturing & regulatory Clinical Phase 2 TA-270/271 COPD (oral, SR) Manufacturing & regulatory Clinical Phase 1 Clinical Phase 2 COPD asthma (inhaled) Pre-clinical Manufacturing & regulatory Clinical Phase 1 Q2.16 Q3.16 Q4.16 Q1.17 Q2.17 Q3.17 Q4.17 Q1.18 Health TA-276 Q1.16 mariposa Product Indication 20 License agreement for HI-164 in China Conditions: Exclusive license for the territories Up-front payment, milestones & royalties (all non-dilutionary) Chinese partner pays full cost of development in the territories mariposa Shanxi Kangbao Biological Products Company Health . 21 Patent Families TA-270 Patent family Purpose Status Substance certain indications Granted 10/2016 2 Substance production Granted 9/2019 3 Improved substance Granted 6/2022 4 Indication: COPD Granted (except pending EU) 7/2025 MH-003 5 Reduce snoring International phase 10/2029 HI-164OV 6 Isolate selection Granted 8/2025 7 Probiotic additive Granted 5/2021 8 Indication: asthma Pending US, EU 9 Commercial isolates Pending US, EU 3/2028 Health 1 mariposa Product Expiry before extensions 9/2029 22 Budget 2017 2018 Total Corporate & admin. $2,121,364 $2,266,643 $5,777,898 $3,286,985 $4,950,701 $3,702,458 $11,940,145 $1,495,790 $5,052,310 $2,111,527 $8,659,627 $401,708 $415,411 $415,411 $1,232,531 $6,574,374 $12,539,786 $8,496,039 $27,610,201 R&D TA-270 R&D HI-164 Patents Total expenses Funds two projects to be in a high value saleable form, including: a) IND preparations b) Clinical trials Health $1,389,891 mariposa 2016 c) Patent and brand build 23 Share ownership % of total WT Trust 16.00% PT Soho Industri Pharmasi Piccadilly Portfolio Pty Ltd 7.21% 7.85% mariposa Shareholder Health 24 License agreement for HI-164 in China Conditions: Exclusive license for the territories Up-front payment, milestones & royalties (all non-dilutionary) Chinese partner pays full cost of development in the territories mariposa Shanxi Kangbao Biological Products Company Health . 25 High Return Potential An investment is an opportunity for significant growth while addressing a significant need mariposa Out-license provides non-dilutive access to an emerging market Corporate filings are in an advanced stage to listing Health 26 Health better health, better life For More Information Please Contact: Health Philip Comans, CEO Email: [email protected] mariposa mariposa 27